Dapagliflozin in Patients with Chronic Kidney Disease

Authors
Hiddo HeerspinkBergur StefánssonDavid Wheeler
Journal
New England Journal of Medicine
Published
September 24, 2020

Abstract

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1056/nejmoa2024816

License

Unknown License
Dapagliflozin in Patients with Chronic Kidney Disease